Taiwan · Delayed Price · Currency is TWD Allied Biotech Statistics
Total Valuation
Allied Biotech has a market cap or net worth of TWD 3.23 billion. The enterprise value is 3.10 billion.
| Market Cap | 3.23B |
| Enterprise Value | 3.10B |
Important Dates
The next estimated earnings date is Monday, August 10, 2026.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | Jun 4, 2026 |
Share Statistics
Allied Biotech has 96.24 million shares outstanding. The number of shares has decreased by -0.11% in one year.
| Current Share Class | 96.24M |
| Shares Outstanding | 96.24M |
| Shares Change (YoY) | -0.11% |
| Shares Change (QoQ) | -0.22% |
| Owned by Insiders (%) | 9.11% |
| Owned by Institutions (%) | 12.89% |
| Float | 56.06M |
Valuation Ratios
The trailing PE ratio is 30.24.
| PE Ratio | 30.24 |
| Forward PE | n/a |
| PS Ratio | 3.67 |
| PB Ratio | 2.53 |
| P/TBV Ratio | 2.53 |
| P/FCF Ratio | 36.61 |
| P/OCF Ratio | 17.53 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.17, with an EV/FCF ratio of 35.17.
| EV / Earnings | 28.95 |
| EV / Sales | 3.53 |
| EV / EBITDA | 16.17 |
| EV / EBIT | 23.72 |
| EV / FCF | 35.17 |
Financial Position
The company has a current ratio of 1.79, with a Debt / Equity ratio of 0.57.
| Current Ratio | 1.79 |
| Quick Ratio | 1.18 |
| Debt / Equity | 0.57 |
| Debt / EBITDA | 3.78 |
| Debt / FCF | 8.23 |
| Interest Coverage | 8.03 |
Financial Efficiency
Return on equity (ROE) is 8.46% and return on invested capital (ROIC) is 9.07%.
| Return on Equity (ROE) | 8.46% |
| Return on Assets (ROA) | 3.63% |
| Return on Invested Capital (ROIC) | 9.07% |
| Return on Capital Employed (ROCE) | 9.93% |
| Weighted Average Cost of Capital (WACC) | 4.33% |
| Revenue Per Employee | 22.00M |
| Profits Per Employee | 2.68M |
| Employee Count | 40 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 1.10 |
Taxes
In the past 12 months, Allied Biotech has paid 29.66 million in taxes.
| Income Tax | 29.66M |
| Effective Tax Rate | 21.68% |
Stock Price Statistics
The stock price has increased by +85.12% in the last 52 weeks. The beta is 0.12, so Allied Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.12 |
| 52-Week Price Change | +85.12% |
| 50-Day Moving Average | 29.92 |
| 200-Day Moving Average | 23.26 |
| Relative Strength Index (RSI) | 58.67 |
| Average Volume (20 Days) | 275,649 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Allied Biotech had revenue of TWD 880.06 million and earned 107.16 million in profits. Earnings per share was 1.11.
| Revenue | 880.06M |
| Gross Profit | 317.17M |
| Operating Income | 130.82M |
| Pretax Income | 136.81M |
| Net Income | 107.16M |
| EBITDA | 186.24M |
| EBIT | 130.82M |
| Earnings Per Share (EPS) | 1.11 |
Balance Sheet
The company has 852.38 million in cash and 725.99 million in debt, with a net cash position of 126.40 million or 1.31 per share.
| Cash & Cash Equivalents | 852.38M |
| Total Debt | 725.99M |
| Net Cash | 126.40M |
| Net Cash Per Share | 1.31 |
| Equity (Book Value) | 1.27B |
| Book Value Per Share | 13.23 |
| Working Capital | 680.84M |
Cash Flow
In the last 12 months, operating cash flow was 184.15 million and capital expenditures -95.94 million, giving a free cash flow of 88.21 million.
| Operating Cash Flow | 184.15M |
| Capital Expenditures | -95.94M |
| Depreciation & Amortization | 55.42M |
| Net Borrowing | -224.01M |
| Free Cash Flow | 88.21M |
| FCF Per Share | 0.92 |
Margins
Gross margin is 36.04%, with operating and profit margins of 14.86% and 12.18%.
| Gross Margin | 36.04% |
| Operating Margin | 14.86% |
| Pretax Margin | 15.55% |
| Profit Margin | 12.18% |
| EBITDA Margin | 21.16% |
| EBIT Margin | 14.86% |
| FCF Margin | 10.02% |
Dividends & Yields
This stock pays an annual dividend of 1.25, which amounts to a dividend yield of 3.73%.
| Dividend Per Share | 1.25 |
| Dividend Yield | 3.73% |
| Dividend Growth (YoY) | 25.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 89.61% |
| Buyback Yield | 0.11% |
| Shareholder Yield | 3.81% |
| Earnings Yield | 3.32% |
| FCF Yield | 2.73% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 7 |